The National Health Service is managing an unprecedented expansion of prescribing for GLP-1 receptor agonist medications — the class of drugs that includes semaglutide, sold commercially as Wegovy and Ozempic — with 200,000 patients currently receiving the treatments and a further 400,000 on waiting lists as NHS England works through its phased rollout programme. The scale of demand reflects both the clinical effectiveness of the medications and the enormous burden of obesity-related illness that has built up across the UK population.
Clinical trial evidence has consistently demonstrated that GLP-1 medications produce substantial and sustained weight reduction — typically between 10 and 20 percent of body weight — in people with significant obesity, with secondary benefits including reduced risk of type 2 diabetes, cardiovascular disease and certain cancers. The economic case for NHS investment in the drugs, modelled by the National Institute for Health and Care Excellence and health economists at several universities, suggested that the long-term reductions in obesity-related healthcare costs would substantially offset the cost of the medications themselves.
However, the rollout has exposed significant challenges around supply chain capacity, prescribing infrastructure and follow-up support. The global demand for GLP-1 medications, driven by their popularity in the private market particularly in the United States, has created intermittent supply disruptions that have affected NHS patients' access to consistent treatment. NHS England has been in negotiations with pharmaceutical manufacturers about priority supply arrangements for NHS patients.
Specialist weight management services, which are expected to oversee prescribing under current NHS guidance, are significantly oversubscribed, with the 400,000 waiting for treatment facing waits of many months in most regions. The government has indicated it is reviewing the prescribing pathway to explore whether primary care — GPs — could take on more of the management of lower-complexity patients.
